FIELD: chemistry.
SUBSTANCE: invention relates to (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate which is a levodopa prodrug and can be used to treat Parkinson's disease, schizophrenia, cognitive disorders, restless legs syndrome, periodic limp movement disorder, tardive dyskinesia, Huntington's disease, arterial hypertension and excessive diurnal drowsiness. The invention also relates to the crystalline form of the said compound, methods of producing said compound and its crystalline form, pharmaceutical compositions and treatment methods.
EFFECT: highly effective treatment.
46 cl, 6 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF LEVODOPA PRODRUG AND METHODS OF USING | 2010 |
|
RU2537137C2 |
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| CARBIDOPA AND L-DOPA PRODRUGS AND USE THEREOF FOR TREATING PARKINSON'S DISEASE | 2015 |
|
RU2743347C2 |
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
| (1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDINE-1-YL)-1-PROPANOL METHANESULFONATE TRIHYDRATE | 1996 |
|
RU2140910C1 |
| PRODRUG OF POLYMERASE NS5B HCV INHIBITOR, METHOD FOR ITS PREPARATION AND APPLICATION | 2017 |
|
RU2644156C1 |
| NOVEL COMPOUND AND ITS APPLICATION IN MEDICINE | 2011 |
|
RU2570900C2 |
| NEW COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM | 2010 |
|
RU2581058C2 |
